Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Abstract

Effective treatment for Sjögren's syndrome (SS) might be developed locally by introducing genes encoding cytokines, which are potentially anti-inflammatory, or by introducing a cDNA encoding a soluble form of a key cytokine receptor, which can act as an antagonist and decrease the availability of certain cytokines, such as soluble tumour necrosis factor alpha receptors. Currently, the preferred choice of viral vector for immunomodulatory gene transfer is recombinant adeno-associated virus. The use of gene transfer to help determine the pathophysiology and to alter the course of the SS-like disease in the NOD mouse model can ultimately lead to the development of new treatments for managing the salivary component in patients with SS.

• Authors: M R Kok, B J Baum, P P Tak, S R Pillemer
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 62 Issue 11 Pg. 1038-46 (Nov 2003) ISSN: 0003-4967 [Print] England
• PMID: 14583564 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Cytokines
• Receptors, Tumor Necrosis Factor

Topics

• Animals
• Cytokines (genetics)
• Dependovirus (genetics)
• Genetic Therapy (methods)
• Genetic Vectors (administration & dosage)
• Humans
• Mice
• Mice, Inbred NOD
• Mice, Transgenic
• Receptors, Tumor Necrosis Factor (genetics)
• Sjogren's Syndrome (immunology, therapy)